Neostigmine antagonism after suxamethonium followed by mivacurium chloride bolus and infusion was studied. Thirty ASA group I or II patients were given mivacurium 0.15 mg/kg followed by infusion during nitrous oxide-enflurane-pethidine anaesthesia. Train of four (TOF) stimuli were applied to the ulnar nerve at the wrist and TOF twitch height and ratio measured by TOF-GUARD nerve stimulator. Mivacurium infusion was titrated to give a 90% block of first twitch height. Patients were randomized into two groups. Group I patients recovered from the mivacurium block spontaneously while Group II patients were given neostigmine 0.05 mg/kg and atropine 0.02 mg/kg. Time to reach train of four ratio (TOFR) of 25%, 50% and 70% were measured. This study demonstrated a mean infusion rate of 5.1±1.8 µg/kg/min to maintain a 90% neuromuscular block. In the spontaneous recovery group, time to reach TOFR of 25%, 50% and 70% were 9.3±2.7 min, 13.5±3.0 min and 16.7±3.0 min respectively while the corresponding times in the neostigmine group were 5.2±1.7 min, 10.9±2.2 min and 16.1±7.4 min respectively. There were significant differences in the time taken to TOFR of 25% (P<0.0001) and 50% (P<0.05) but no difference in the time taken for TOFR to return to 70%. We concluded that mivacurium is suitable for use in caesarean section despite a decrease in plasma cholinesterase activity. Neostigmine antagonism is not required as a routine.
Mivacurium is a relatively new benzylisoquinolinium nondepolarizing muscle relaxant with a short duration of action [1] [2] [3] [4] due to rapid hydrolysis by plasma cholinesterase (also known as pseudocholinesterase or butyrylcholinesterase) at a rate 70-88% of that of suxamethonium 2 . Because of its pharmacokinetics, it is suitable for administration by continuous infusion. Reversal of mivacurium block with an anticholinesterase is not routinely required [5] [6] [7] .
Previous studies proved that there is a reduction of plasma cholinesterase activity of up to 30% in the third trimester of pregnancy and it will remain depressed in the postpartum period [8] [9] [10] [11] . Infusion requirements may also be altered because of pharmacokinetic changes such as the increase in intravascular volume and increased renal clearance during pregnancy in addition to a decrease in plasma cholinesterase activity.
The use of mivacurium in pregnancy has not been studied. This study was designed to investigate the dosage requirement of mivacurium during continuous infusion in pregnancy and to find out whether an antagonist such as neostigmine is necessary to reverse the mivacurium-induced block.
METHODS AND PATIENTS
After gaining permission from the Hospital Authority Ethics Committee, 30 consecutive patients were included in the study with informed consent obtained. They were ASA class I or II women for caesarean section at Tsan Yuk Hospital. Patients were excluded if they: (1) had a history of asthma or allergy, neuromuscular diseases, liver or renal diseases; (2) were taking any drugs that affect neuromuscular transmission or pseudocholinesterase activity; (3) were suffering from pregnancy-induced hypertension; (4) were less than 37 weeks gestation or (5) were unable to understand the instructions or give informed consent.
The patients were randomized into two groups before induction. Thirty envelopes containing notes stating either "Group I" or "Group II" were attached to 30 data sheets and consent forms. Group I patients would be allowed to recover spontaneously after mivacurium infusion while Group II patients would receive neostigmine. The investigator was required to draw a set of envelope and forms at random and follow what was written in the envelope.
All patients were premedicated with oral ranitidine 150 mg two hours before the operation. Sodium citrate 0.3M 30 ml orally was given when patients arrived at the theatre suite. When patients arrived at the theatre, they were put in a left lateral tilt on the operating table and preoxygenated for at least three minutes. Monitors measuring vital signs such as blood pressure, pulse, electrocardiogram and pulse oximetry were connected. Supramaximal stimulus and baseline twitch height were measured using a TOF-GUARD nerve stimulator before induction. Rapid sequence induction was employed with cricoid pressure, thiopentone 4 mg/kg IV and suxamethonium 2 mg/kg IV. Patients were then intubated and ventilated with IPPV using a Manley MP3 ventilator and a tidal volume of 10 ml/kg and a minute volume of 100 ml/kg/min to maintain an end-tidal CO 2 of 4.5 to 5.0 kPa. Anaesthesia was maintained with 50% nitrous oxide, 50% oxygen and 0.8% endtidal enflurane. Inspiratory and end-tidal gas concentrations were measured with a Datex Capnomac Ultima anaesthetic agent monitor. Level of neuromuscular blockade was monitored with a TOF-GUARD peripheral nerve stimulator with the cutaneous electrodes applied over the ulnar nerve at the wrist. Supramaximal square wave stimuli of 0.2 ms duration in the train-of-four (TOF) mode at 2 Hz every 15s were delivered.
A mivacurium bolus 0.15 mg/kg (2 x ED 95 ) was given in about 10s through a large peripheral IV catheter when the first TOF twitch (T1) returned to 70% of the baseline twitch height (BTH). The block was then allowed to regress until the T1 returned to 10% BTH, then a mivacurium infusion of 6 µg/kg/min was started using a Graseby 3100 infusion pump. The infusion rate was titrated manually by ±2 µg/kg/min every five minutes to aim at a T1 of 10% of the BTH (+2 µg/kg/min if T1>12% and -2 µg/kg/min if T1<8%).
After the baby was delivered, pethidine 1 mg/kg IV was administered and anaesthesia maintained with 70% nitrous oxide, 30% oxygen and 0.4% end-tidal enflurane. The mivacurium infusion was stopped when the surgeon finished skin closure. Group I patients were allowed to recover spontaneously and anaesthesia maintained with 70% N 2 O, 30% O 2 and 0.4% enflurane until TOFR reached 70%. Group II patients received neostigmine 0.05 mg/kg IV and atropine 0.02 mg/kg IV immediately after the mivacurium infusion was stopped and 70% N 2 O, 30% O 2 and 0.4% enflurane was maintained until TOFR returned to 70%. Anaesthesia was stopped and the patients were then turned lateral for extubation when fully awake.
Data collection included demographic data, baseline twitch height and recovery times of suxamethonium and mivacurium bolus. Average mivacurium infusion rate was calculated by dividing the total infused dose by the body weight and the total duration of infusion. Recovery times to TOFR of 25%, 50% and 70% were measured. Any side-effects of mivacurium such as flushing or decreased mean arterial pressure were recorded.
Parametric data were analysed using two-tailed Student's t-test. Data were expressed as mean ± standard deviation (SD). Non-parametric data were analysed with Mann Whitney U test. Statistical significance was accepted when P<0.05.
RESULTS
There were no significant differences in the demographic data such as age, weight and height between the two groups of patients (Table 1) . Moreover, intraoperative parameters were not significantly different between the two groups ( Table 2) .
Mivacurium infusion was not started in three patients because the operation finished before the T1 returned to 10% BTH after the mivacurium bolus. In these patients, time when infusion stopped was taken as the time when T1 returned to 10% BTH.
Duration of action of suxamethonium (time of injection until T1 returned to 70% BTH) was 12.5±3.0 min; duration of action of mivacurium (time of bolus injection until T1 returned to 10% BTH) was 14.2±5.5 min. The average infusion rate of miva- curium required to maintain a T1 of 10% BTH during the operation was 5.1±1.8 µg/kg/min (Table 3 ). There was some correlation between the duration of action of suxamethonium and the duration of action of mivacurium bolus (r=0.54, P=0.0019).
After infusion was stopped, the time taken for the TOFR of patients in the neostigmine group (group II) to return to 25% and 50% were significantly shorter than in the spontaneous recovery group (group I). The time taken for the TOFR to return to 70% and the time taken from infusion stopped until extubation were not different (Table 4) .
Serious side-effects of mivacurium did not occur in any patient except mild transient hypotension in one patient who responded well to intravenous fluid infusion.
DISCUSSION
The reversal of neuromuscular blocking effects of mivacurium by neostigmine are paradoxical. On one hand neostigmine antagonizes the nondepolarizing block but it also binds to and inhibits plasma cholinesterase to a certain extent, thereby decreasing the degradation rate of mivacurium 13, 14 . As a result, shorter times were taken to reach TOFR of 25% and 50% in the neostigmine group than in the spontaneous recovery group. Binding of neostigmine to plasma cholinesterase may become more obvious at the later part of the recovery so that there were no statistical differences in the time taken to reach TOFR of 70% and time elapsed before extubation.
We intended to extubate the patients when their TOFRs returned to 70%. Despite this, adequate respiratory effort and tidal volume may be achieved before the TOFR reaches 70% because the diaphragm and the other respiratory muscles recover faster than the limb muscles 21 . In actual clinical practice the patient may be able to breathe spontaneously and be extubated before the TOFR ratio reaches 70%.
Neostigmine antagonism after mivacurium infusion is often unnecessary for patients with normal plasma cholinesterase activity (i.e. within the range observed in parturients) provided that clinical signs of recovery and neuromuscular function are monitored. Edrophonium, which does not inhibit plasma cholinesterase, seems to be a better choice than neostigmine if reversal of the neuromuscular block is required 6, 7, 15 .
It would be ideal to measure plasma cholinesterase activity before and during the operation but enzyme assay was not readily available to the authors. Blitt et al 9 Data are expressed as mean (SD). Duration of action of mivacurium was taken as the time from injection of mivacurium bolus to T1 returned to 10% BTH. Average infusion rate was calculated using the formula: average infusion rate =total infused dose / body weight / infusion duration. Data are expressed as mean (SD). Duration of action of suxamethonium was taken as the time from injection of suxamethonium to T1 returned to 70% BTH. Duration of action of mivacurium was taken as time from injection of mivacurium bolus to T1 returned to 10% BTH. Average infusion rate was calculated using the formula: average infusion rate = total infused dose / body weight / infusion duration. Statistical significance was taken as P<0.05. from late pregnancy into the early postpartum period. When the duration of action of mivacurium and the average infusion rate demonstrated in this study were compared with studies in non-pregnant normal adults, results were similar in two recent studies 15, 16 but mivacurium requirement was significantly less in three other studies 3, 4, 18 . The different anaesthetic techniques employed may have contributed to these differences. An increase in the volume of distribution in parturients which lowers the plasma level and increases the mivacurium requirement may have been an influence.
The most comparable study was from Goldhill 18 . In his study anaesthesia was maintained with nitrous oxide, enflurane, propofol and alfentanil in nonpregnant adults. Mivacurium infusion rate to maintain a T1 of 1 to 10% BTH was found to be 6.6±2.6 µg/kg/min which was higher than that found in the present study. He also demonstrated that the recovery time to TOFR of 70% was 11.2±2.5 min if neostigmine was given and 17.1±5.1 min if allowed to recover spontaneously. Thus he found that nonpregnant patients recovered more quickly when neostigmine reversal was given. This was quite different from what we found in parturients.
The body weight of the parturients includes the placenta, the amniotic fluid and the fetus. Similar to other nondepolarizing muscle relaxants, mivacurium is highly ionized in the blood and thus will not cross the placenta and be distributed to the placenta and the fetus. Taking this into account, the 'body weight' may have been overestimated, leading to an underestimation of the average infusion rate during calculation.
Compared with other studies on non-pregnant adults, this study was complicated by the use of suxamethonium. Savarese pointed out that it usually takes 198 seconds after mivacurium bolus of 2 x ED 95 to establish adequate relaxation for intubation 1 . In the obstetric patients this time lag is undesirable because of the risk of regurgitation and aspiration. Increasing the dosage of mivacurium to even 4 x ED 95 only shortens the time interval to 114 seconds, but the duration of action would be prolonged and the incidence of excessive histamine release would be increased 1 . Although suxamethonium is also metabolized by plasma cholinesterase leading to alteration in the pseudocholinesterase activity and mivacurium pharmacokinetics, it was still used as the relaxant for intubation for patient's safety.
The mean duration of action of suxamethonium was found to be 12.5±3.0 min which was longer than the mean time interval from the injection of suxamethonium to clamping of umbilical cord of 9.5±3.1 min. Thus mivacurium was usually given after the baby was delivered.
It has been shown that volatile agents such as enflurane 18 , isoflurane 16 and nitrous oxide but not halothane 19 potentiate the effects of mivacurium in normal adults. To prevent patients' awareness before regaining adequate muscle power, in our study enflurane was continued after the operation ended until the TOFR returned to 70%. Mivacurium action may theoretically be potentiated by enflurane leading to an increase in the time required for the TOFRs to return to the specific values. Whether this occurs and the extent of potentiation in obstetric patients needs to be further evaluated.
To conclude, mivacurium can be used for caesarean section although it is well known that parturients usually have a decreased plasma cholinesterase activity. Mivacurium infusion dosage is predictable and a lower rate of infusion is suggested with monitoring of neuromuscular function. Neostigmine is not routinely required to reverse the mivacurium block because it does not decrease the time required before extubation of the patients.
